← All trials
NCT04759105
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 17, 2020
- Primary completion
- Jul 31, 2021
- Completion date
- Jun 30, 2022
- First posted
- Feb 18, 2021
- Last posted
- Feb 18, 2021
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Campus Bio-Medico UniversityLead sponsor
- Campus Bio-Medico UniversityReponsible party - principal investigator
- A.O. Ospedale Maggiore di LodiCollaborator
- Center for Outcomes Research and Clinical Epidemiology, ItalyCollaborator
- University of Roma La SapienzaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.